Hypercholesterolemia, familial, 1

This Phase 2 trial tests a new drug called HDY015, which combines two medicines (QCZ484 and inclisiran) into a single injection. The goal is to see if it can safely lower both blood pressure and cholesterol in people who have both conditions. About 120 adults aged 18-75 with hype…

This early-stage trial tests a new CRISPR-based treatment called CTX310 for people with severe cholesterol and triglyceride problems that don't improve with standard therapies. The treatment uses a tiny fat bubble to deliver gene-editing tools that turn off a gene linked to high …

This study tests whether a daily probiotic called AKM Lab-01 can safely lower cholesterol levels in people with high cholesterol. About 60 adults aged 40-60 will take either the probiotic or a placebo for a period, and researchers will compare changes in their blood cholesterol a…

This study tests a new drug called obicetrapib against another drug, bempedoic acid, to see which lowers 'bad' cholesterol more effectively. It involves 426 adults with high cholesterol who are already on maximum cholesterol medications and are at high risk for heart problems. Th…

This registry is tracking 1,500 Italian patients who are prescribed alirocumab 300 mg injections for high cholesterol. Researchers want to see how consistently patients take the medication and how well it lowers their cholesterol in real-life settings. The study also monitors sid…

This study tests whether adding inclisiran (a twice-yearly injection) to standard care lowers LDL cholesterol more than standard care alone in 520 patients who recently had a heart attack, stroke, or urgent heart procedure. Participants are randomly assigned to receive inclisiran…

This study aims to screen 300 children aged 2 to 18 for familial hypercholesterolemia, a genetic condition that causes very high cholesterol and greatly increases heart disease risk in adulthood. A small blood sample is taken after fasting to measure cholesterol levels. The goal …

This study will look at how consistently nearly 6,000 adults in Italy take three newer cholesterol-lowering drugs (inclisiran, evolocumab, and alirocumab) over the long term. Researchers will analyze prescription records to measure adherence and persistence in everyday medical pr…